Here are the latest quarterly results of DISHMAN CARBOGEN AMCIS. For more details, see the DISHMAN CARBOGEN AMCIS financial fact sheet and DISHMAN CARBOGEN AMCIS share price and chart. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Jun-20* |
3
Sep-20* |
3
Dec-20* |
3
Mar-21* |
3
Jun-21* |
3
Sep-21* |
3
Dec-21* |
3
Mar-22* |
8-Qtr Chart Click to enlarge |
|
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | Rs m | 4,744 | 4,395 | 4,686 | 5,293 | 5,507 | 4,589 | 5,621 | 5,690 | |
Other income | Rs m | 86 | 149 | 90 | 60 | 104 | 96 | 190 | 44 | |
Turnover | Rs m | 4,830 | 4,544 | 4,775 | 5,353 | 5,611 | 4,685 | 5,811 | 5,734 | |
Expenses | Rs m | 4,314 | 3,594 | 4,060 | 4,410 | 4,501 | 3,597 | 4,526 | 5,470 | |
Gross profit | Rs m | 431 | 801 | 626 | 661 | 1,006 | 967 | 1,095 | 99 | |
Depreciation | Rs m | 737 | 784 | 791 | 768 | 747 | 741 | 750 | 839 | |
Interest | Rs m | 116 | 126 | 144 | 91 | 124 | 137 | 151 | 156 | |
Profit before tax | Rs m | -336 | 40 | -219 | -138 | 240 | 186 | 385 | -853 | |
Tax | Rs m | -122 | -34 | -58 | 1,212 | 80 | 74 | 31 | -407 | |
Profit after tax | Rs m | -214 | 74 | -161 | -1,350 | 160 | 112 | 354 | -446 | |
Gross profit margin | % | 9.1 | 18.2 | 13.4 | 12.5 | 18.3 | 21.1 | 19.5 | 1.7 | |
Effective tax rate | % | 36.2 | -85.9 | 26.6 | -879.1 | 33.2 | 39.8 | 8.1 | 47.7 | |
Net profit margin | % | -4.5 | 1.7 | -3.4 | -25.5 | 2.9 | 2.4 | 6.3 | -7.8 | |
Diluted EPS | Rs | -1.4 | 0.5 | -1.0 | -8.6 | 1.0 | 0.7 | 2.3 | -2.8 | |
Diluted EPS (TTM) | Rs | 7.9 | 5.8 | 2.7 | -10.5 | -8.1 | -7.9 | -4.6 | 1.1 | |
![]() |
On Monday, despite opening the day with losses, Indian share markets reversed course as the session progressed to end higher.
The company has also announced a final dividend of Rs 23 per equity share recently.
It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.
Here's why Divi's Lab's stock fell over 10% in two days.
For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.
During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.
More Views on NewsThis aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.
The good side of a market correction? Investors get consistent compounding stocks at a discount.
The auto index is outperforming the Nifty by a mile. Have auto stocks finally bottomed out?
Mutual funds are buying shares at a time when FIIs are consistently selling. Here are 5 stocks where MF holdings has increased for the past 4 quarters.
Global markets have become volatile, sending chills through the crude oil market.
More